PharmiWeb11h
Libtayo® (cemiplimab) Now Available on the National Health Service in Scotland for Patients with Recurrent or Metastatic Cervical Cancer
Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...
Cervical cancer meant I needed a hysterectomy at 24. Now I’m grieving the children I’ll never carry
Sierra Boughton's doctor insisted her heavy, painful periods were normal, but then at just 24, she received devastating news.
Lung cancer among non-smokers increases; air pollution could be culprit: Lancet report
The findings of the study showed that adenocarcinoma, accounted for 53-70 per cent of the lung cancer cases in non-smokers globally in 2022.